• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用真正的磷酸供体三磷酸尿苷对人脱氧胞苷激酶进行动力学分析。

Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate.

作者信息

Hughes T L, Hahn T M, Reynolds K K, Shewach D S

机构信息

Department of Pharmacology, University of Michigan Medical School, Ann Arbor 48109, USA.

出版信息

Biochemistry. 1997 Jun 17;36(24):7540-7. doi: 10.1021/bi970059r.

DOI:10.1021/bi970059r
PMID:9200705
Abstract

Deoxycytidine kinase is the rate-limiting process in the activation for several clinically important antitumor agents. Previous studies have focused on deoxycytidine (dCyd) and adenosine triphosphate (ATP) as substrates for this enzyme. In view of recent data indicating that uridine triphosphate (UTP) is the physiologic phosphate donor for this enzyme, a study of the kinetic properties of dCyd kinase with dCyd and UTP was undertaken. The results presented here demonstrate that UTP and ATP produce kinetically distinguishable differences in nucleoside phosphorylation by dCyd kinase. At high dCyd concentrations, dCyd kinase exhibited substrate activation with ATP. In contrast, in the presence of UTP, substrate inhibition was observed at concentrations of dCyd greater than 3 microM. Inhibition by dCyd was noncompetitive with respect to UTP and could not be reversed by a 200-fold increase in UTP concentration, indicating that the inhibition was not due to dCyd binding at the nucleotide binding site. The kinetic mechanism for dCyd kinase was determined with dCyd and UTP as substrates. UTP was the preferred phosphate donor with a true Km value of 1 microM compared to 54 microM with ATP, resulting in a 50-fold greater substrate efficiency for UTP. Although the double-reciprocal plots with UTP produced parallel lines, initial velocity plots with other phosphate donors and product inhibition studies indicated that dCyd kinase formed a ternary complex with its substrates. The parallel lines with UTP were apparently due to a low dissociation constant for UTP, which was calculated as more than 13-fold lower than its Km value. Analysis of product inhibition studies indicated that dCyd kinase followed an ordered A-B random P-Q reaction sequence, with UTP as the first substrate to bind. In contrast, previous results demonstrated a random bi-bi sequence for dCyd kinase in the presence of ATP. The combined results indicate that the enzyme can follow a random bi-bi reaction sequence, but with UTP as the phosphate donor, the addition of nucleotide prior to dCyd is strongly preferred. The noncompetitive substrate inhibition, which was independent of UTP concentration, indicates that high concentrations of dCyd promote addition of the nucleoside prior to UTP, resulting in a lower velocity.

摘要

脱氧胞苷激酶是几种临床上重要的抗肿瘤药物激活过程中的限速环节。以往的研究主要聚焦于脱氧胞苷(dCyd)和三磷酸腺苷(ATP)作为该酶的底物。鉴于最近的数据表明三磷酸尿苷(UTP)是该酶的生理性磷酸供体,因此开展了一项关于dCyd激酶与dCyd和UTP的动力学特性的研究。此处呈现的结果表明,UTP和ATP在dCyd激酶介导的核苷磷酸化过程中产生了动力学上可区分的差异。在高dCyd浓度下,dCyd激酶对ATP表现出底物激活作用。相反,在UTP存在的情况下,当dCyd浓度大于3 microM时观察到底物抑制现象。dCyd的抑制作用对UTP而言是非竞争性的,并且UTP浓度增加200倍也无法逆转这种抑制作用,这表明该抑制作用并非由于dCyd在核苷酸结合位点的结合所致。以dCyd和UTP作为底物确定了dCyd激酶的动力学机制。UTP是首选磷酸供体,其真实Km值为1 microM,而ATP的Km值为54 microM,这使得UTP的底物效率高出50倍。尽管与UTP的双倒数图产生了平行线,但与其他磷酸供体的初速度图以及产物抑制研究表明,dCyd激酶与其底物形成了三元复合物。与UTP的平行线显然是由于UTP的解离常数较低,经计算其比Km值低13倍以上。产物抑制研究分析表明,dCyd激酶遵循有序的A - B随机P - Q反应序列,其中UTP是第一个结合的底物。相反,先前的结果表明在ATP存在下dCyd激酶遵循随机双底物双产物序列。综合结果表明,该酶可以遵循随机双底物双产物反应序列,但以UTP作为磷酸供体时,强烈优先于dCyd先添加核苷酸。与UTP浓度无关的非竞争性底物抑制表明,高浓度的dCyd会促进在UTP之前添加核苷,从而导致速度降低。

相似文献

1
Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate.使用真正的磷酸供体三磷酸尿苷对人脱氧胞苷激酶进行动力学分析。
Biochemistry. 1997 Jun 17;36(24):7540-7. doi: 10.1021/bi970059r.
2
A pre-steady-state kinetic analysis of substrate binding to human recombinant deoxycytidine kinase: a model for nucleoside kinase action.底物与重组人脱氧胞苷激酶结合的前稳态动力学分析:核苷激酶作用模型
Biochemistry. 1999 Jun 29;38(26):8555-61. doi: 10.1021/bi990162b.
3
Nucleotide specificity of human deoxycytidine kinase.人类脱氧胞苷激酶的核苷酸特异性
Mol Pharmacol. 1992 Sep;42(3):518-24.
4
A critical role for uridine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-beta-D-arabinofuranosylcytosine phosphorylation in human leukemia cells.尿苷酸在人白血病细胞中脱氧胞苷激酶调节及1-β-D-阿拉伯呋喃糖基胞嘧啶磷酸化浓度依赖性方面的关键作用。
Cancer Res. 1991 May 15;51(10):2559-65.
5
Hydrodynamic and spectroscopic studies of substrate binding to human recombinant deoxycytidine kinase.底物与人重组脱氧胞苷激酶结合的流体动力学和光谱学研究
Nucleosides Nucleotides Nucleic Acids. 2003 Feb;22(2):175-92. doi: 10.1081/NCN-120019513.
6
Nucleoside triphosphate donors for nucleoside kinases: donor properties of UTP with human deoxycytidine kinase.核苷激酶的核苷三磷酸供体:UTP对人脱氧胞苷激酶的供体特性
Biochem Biophys Res Commun. 1995 Nov 2;216(1):42-8. doi: 10.1006/bbrc.1995.2589.
7
Role of uridine triphosphate in the phosphorylation of 1-beta-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells.三磷酸尿苷在艾氏腹水瘤细胞对1-β-D-阿拉伯呋喃糖基胞嘧啶磷酸化过程中的作用。
Cancer Res. 1987 Apr 1;47(7):1820-4.
8
Structural basis for the preference of UTP over ATP in human deoxycytidine kinase: illuminating the role of main-chain reorganization.人脱氧胞苷激酶中尿苷三磷酸(UTP)优于三磷酸腺苷(ATP)的偏好性的结构基础:揭示主链重排的作用
Biochemistry. 2006 Jan 17;45(2):452-61. doi: 10.1021/bi0518646.
9
Chiral influences of feedback inhibition with dCTP on murine deoxycytidine kinase.dCTP反馈抑制对小鼠脱氧胞苷激酶的手性影响。
Nucleic Acids Symp Ser. 1997(37):181-2.
10
Differences in kinetic properties of pure recombinant human and mouse deoxycytidine kinase.纯重组人脱氧胞苷激酶和小鼠脱氧胞苷激酶动力学特性的差异。
Biochem Pharmacol. 1995 Jul 17;50(2):163-8. doi: 10.1016/0006-2952(95)00129-n.

引用本文的文献

1
4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress.4'-乙炔基-2'-脱氧胞苷(EdC)通过诱导复制应激优先靶向淋巴瘤和白血病亚型。
Mol Cancer Ther. 2024 May 2;23(5):683-699. doi: 10.1158/1535-7163.MCT-23-0487.
2
From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia.从药物重定位到基于结构的药物设计方法解决急性淋巴细胞白血病。
Nat Commun. 2023 May 29;14(1):3079. doi: 10.1038/s41467-023-38668-2.
3
Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.
双蛋白激酶和核苷激酶调节剂用于合理设计多药理学。
Nat Commun. 2017 Nov 10;8(1):1420. doi: 10.1038/s41467-017-01582-5.
4
Metastatic pancreatic cancer: Is there a light at the end of the tunnel?转移性胰腺癌:隧道尽头有曙光吗?
World J Gastroenterol. 2015 Apr 28;21(16):4788-801. doi: 10.3748/wjg.v21.i16.4788.
5
Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials.吉西他滨固定剂量率输注治疗胰腺癌:随机对照试验的荟萃分析
Diagn Pathol. 2014 Nov 25;9:214. doi: 10.1186/s13000-014-0214-8.
6
Gemcitabine treatment of rat soft tissue sarcoma with phosphatidyldiglycerol-based thermosensitive liposomes.吉西他滨联合基于磷脂酰甘油的热敏脂质体治疗大鼠软组织肉瘤
Pharm Res. 2014 Sep;31(9):2276-86. doi: 10.1007/s11095-014-1322-6. Epub 2014 Mar 6.
7
Post-translational phosphorylation of serine 74 of human deoxycytidine kinase favors the enzyme adopting the open conformation making it competent for nucleoside binding and release.丝氨酸 74 的翻译有多种译法,包括 Ser74、Serine74、S74 等,这里为了保持一致,采用了 Ser74 的译法。 人脱氧胞苷激酶丝氨酸 74 的翻译有多种译法,包括 Ser74、Serine74、S74 等,这里为了保持一致,采用了 Ser74 的译法。 人脱氧胞苷激酶 Ser74 的翻译有多种译法,包括 Ser74、Serine74、S74 等,这里为了保持一致,采用了 Ser74 的译法。 人脱氧胞苷激酶 Ser74 的磷酸化有利于酶采取开放构象,使其能够进行核苷结合和释放。
Biochemistry. 2011 Apr 12;50(14):2870-80. doi: 10.1021/bi2001032. Epub 2011 Mar 16.
8
Elucidation of different binding modes of purine nucleosides to human deoxycytidine kinase.嘌呤核苷与人类脱氧胞苷激酶不同结合模式的阐明。
J Med Chem. 2008 Jul 24;51(14):4219-25. doi: 10.1021/jm800134t. Epub 2008 Jun 21.
9
Structural basis for substrate promiscuity of dCK.脱氧胞苷激酶(dCK)底物选择性的结构基础
J Mol Biol. 2008 May 2;378(3):607-21. doi: 10.1016/j.jmb.2008.02.061. Epub 2008 Mar 3.
10
Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.1-(3-C-乙炔基-β-D-核糖戊呋喃糖基)胞嘧啶(ECyd,TAS-106)对已建立的吉西他滨(dFdCyd)耐药人胰腺癌细胞系的潜在抗肿瘤活性。
Cancer Sci. 2005 May;96(5):295-302. doi: 10.1111/j.1349-7006.2005.00046.x.